Paper Details

  1. Home
  2. Paper Details

A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy.

Author: AarnoutseR E, BlokW L, BurgerD M, DielemanJ P, HugenP W, LangeJ M, MeenhorstP L, MulderJ W, PrinsJ M, ReissP, ten VeenJ H, van der MeerJ T, van der PollT

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Indinavir + ritonavir regimens are effective in controlling HIV with improved pharmacokinetic properties allowing twice-daily dosing. A cohort-based survey of 132 patients found that both 800-mg indinavir + 100-mg ritonavir and 400-mg indinavir + 400-mg ritonavir regimens twice daily were associated with good viral suppression and were generally well-tolerated. However, patients in the 400/400 group were more likely to discontinue treatment.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To describe the pharmacokinetics, safety, and efficacy of twice-daily indinavir + ritonavir regimens DESIGN: A cohort-based survey of HIV-infected patients who either used indinavir 800 mg + ritonavir 100 mg twice daily or indinavir 400 mg + ritonavir 400 mg twice daily. METHODS: Data w...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/00042560-200103010-00003

データ提供：米国国立医学図書館（NLM）

A Retrospective, Cohort-Based Survey of Patients Using Twice-Daily Indinavir + Ritonavir Combinations: Pharmacokinetics, Safety, and Efficacy

In the field of HIV treatment, optimizing drug regimens is a constant pursuit. This retrospective cohort study evaluated the pharmacokinetics, safety, and efficacy of twice-daily indinavir + ritonavir combinations in HIV-infected patients.

Twice-Daily Regimens: A New Approach to HIV Treatment

The study compared two twice-daily regimens, indinavir 800 mg + ritonavir 100 mg and indinavir 400 mg + ritonavir 400 mg. Both regimens demonstrated improved pharmacokinetic properties compared to the previous three-times-daily indinavir regimen. The most frequently observed side effects were nausea and vomiting, which occurred more frequently in the 400/400 group. The study also found that patients switching from the three-times-daily regimen to the twice-daily regimens maintained or improved their viral load suppression.

Navigating the Shifting Sands of HIV Treatment

This study highlights the evolving landscape of HIV treatment, with the emergence of more convenient and effective regimens. It underscores the importance of continued research to optimize treatment strategies and improve patient outcomes. The study also highlights the need for prospective trials to further evaluate the long-term efficacy and safety of these twice-daily regimens.

Dr.Camel's Conclusion

This study provides valuable information regarding the pharmacokinetics, safety, and efficacy of twice-daily indinavir + ritonavir combinations in HIV-infected patients. The findings suggest that these regimens offer a more convenient and potentially equally effective alternative to the traditional three-times-daily regimen. Further research is needed to confirm these findings and to explore the long-term implications of these regimens.
Date :
  1. Date Completed 2001-04-12
  2. Date Revised 2020-09-30
Further Info :

Pubmed ID

11242194

DOI: Digital Object Identifier

10.1097/00042560-200103010-00003

Related Literature

Article Analysis
・Side Effects of indinavir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.